Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 57, Issue 5, 2013, Pages 583-586

  Ledder, Oren D ^a   Lemberg, Daniel A ^b   Ooi, Chee Y ^b   Day, Andrew S ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

drug reaction; inflammatory bowel disease; pancreatitis; thiopurine

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELASTOGRAPHY; ENTERIC FEEDING; ENTERITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT CONTRAINDICATION; ULTRASOUND;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICAL RECORDS; PANCREATITIS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84888134529     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31829f16fc     Document Type: Article

References (25)

1. Nielsen OH, Vainer B, Rask-Madsen J. Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001;15:1699-708
2. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 T lymphocytes. J Clin Invest 2003;111:1133-45
3. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962;49:592-3
4. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut 2002;50:485-9
5. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-Analysis. Ann Intern Med 1995;123: 132-42
6. Pearson DC, May GR, Fick GH, et al. Azathioprine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2000; 1:CD000067
7. Yu P, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009;27:609-21
8. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects ina population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004;13:563-7
9. Balani AR, Grendell JH. Drug-induced pancreatitis: Incidence, management and prevention. Drug Saf 2008;31:823-37
10. Nitsche CJ, Jamieson N, Lerch MM, et al. Drug induced pancreatitis. Best Pract Res Clin Gastroenterol 2010;24:143-55
11. Floyd A, Pedersen L, Nielsen GL, et al. Risk of acute pancreatitis in users of azathioprine: A population-based case-control study. Am J Gastroenterol 2003;98:1305-8
12. Ooi CY, Bohane TD, Lee D, et al. Thiopurine metabolite monitoring in pediatric inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25:941-7
13. Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine induced pancreatitis. Aliment Pharmacol Ther 2008;28:623-8
14. Parenti DM, Steinberg W, Kang P. Infectious causes of acute pancreatitis. Pancreas 1996;13:356-71
15. Sibert Jr. Pancreatitis in children. A study in the North of England. Arch Dis Child 1975;50:443-8
16. Pitchumoni CS, Rubin A, Das K. Pancreatitis in inflammatory bowel disease. J Clin Gastroenterol 2010;44:246-53
17. Foutch PG, Ferguson DR. Duodenal Crohn's disease complicated by common bile duct obstruction: Report of a case and review of the literature. Am J Gastroenterol 1984;79:520-4
18. Ravi K, Chari ST, Vege SS, et al. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis 2009; 15:1326-30
19. Saeki K, Hozawa S, Miyata N, et al. IgG4-negative autoimmune pancreatitis with sclerosing cholangitis and colitis: Possible association with primary sclerosing cholangitis? Intern Med 2008;47:943-8
20. Van Dieren JM, Hansen BE, Kuipers EJ, et al. Meta-Analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007;26:643-52
21. McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002;122:838-9
22. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004;20:843-50
23. Alexander S, Dowling D. Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine. Intern Med J 2005;35:570-1
24. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:220-7
25. Sokol H, Seksik P, Carrat F, et al. Usefullness of co-Treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8